

## PATIENT DETAILS

\*Affix patient Addressograph if available

SURNAME: \_\_\_\_\_ FIRSTNAME(S): \_\_\_\_\_

DATE OF BIRTH: \_\_\_\_/\_\_\_\_/\_\_\_\_ MRN: \_\_\_\_\_



## NDMS Multiple Sclerosis Patient Eligibility Form Natalizumab (Tysabri®)

Form must be completed in full and saved securely in the patient's medical record for audit purposes only

TREATMENT	HSE APPROVED INDICATION	ICD10	Protocol Code
Natalizumab (Tysabri®)	Natalizumab (Tysabri®) is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups:		
	Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) ( <i>for exceptions and information about washout periods see AHDMP Protocol MS101a&amp;b and the SPC</i> )	G35	MS101a
	<b>OR</b> Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI	G35	MS101b

ELIGIBILITY		YES	NO
Indication as per protocol MS101a or MS101b			
Eligibility criteria in protocol MS101a or MS101b have been met			
EXCLUSIONS		YES	NO
All exclusion criteria laid out in protocol MS101a & MS101b have been considered.			
PREVIOUS MEDICATION(S) FOR MULTIPLE SCLEROSIS			
Name of Medicine (in order of use; 1. = first line etc.)	Reason for change in treatment (please tick)		
	Adverse Event	Loss of Response	Other Reason
1.			
2.			
3.			
4.			
5.			
PRESCRIBER DETAILS			
Prescriber Name			
Medical Registration Number			
ELIGIBILITY FORM COMPLETED BY			
Name			
Date			

Protocol: MS - Natalizumab	Published: 29/05/2017 Update: January 2022 Review: January 2024	Version number: 5
AHDMP Protocol Code: MS101a&b	Approver: Prof Christopher McGuigan as Multiple Sclerosis Lead for the National Clinical Programme for Neurology	Page 1 of 1
<p>The information contained in this document is a statement of consensus from the National Clinical Programme for Neurology regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p>This information is valid only on the day of printing, for any updates please check <a href="https://www.hse.ie/eng/about/who/acute-hospitals-division/drugs-management-programme/ndms/">https://www.hse.ie/eng/about/who/acute-hospitals-division/drugs-management-programme/ndms/</a></p>		